Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechs face potential U.S.
WESTON (dpa-AFX) - Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the
ADUHELM continued to reduce two key Alzheimer's disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that clinical
By Michael Dabaie Biogen Inc. unveiled new data showing that after nearly two and a half years of treatment Aduhelm continues to reduce underlying pathologies of Alzheimer's disease. ... | March 16, 2022
CAMBRIDGE, Mass., March 16, 2022(Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer's Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3